Biomedical Catalyst – Digital Healthcare Platform for Early Dementia Diagnosis

生物医学催化剂 — 痴呆症早期诊断数字医疗平台

• 批准号: MC_PC_13034
• 负责人: Daniel Rueckert
• 金额: $ 44.07万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_13034
• 关键词: Biomedical; Catalyst; Digital; Healthcare; Platform

Most of the 700,000 people in the UK with dementia have not received a formal diagnosis, so are denied access to beneficial treatments. The current NHS approach is slow (often more than 12 months) and often of low quality. This project will develop a novel digital healthcare system that will allow dementia diagnoses to be made quickly, cost effectively, and earlier in the disease course. It makes a novel combination of computer-based tests of memory and thinking and computerized analysis of MRI brain scans, which have been used in research for several years. It will provide support in diagnosis, making available the quality of information currently only available in highly specialist centres to doctors treating all patients, with the aim of reducing time to diagnosis to 3 months. We will build and test a prototype and demonstrate its value before developing a refined prototype that can be rolled-out nationally.

在英国70万痴呆症患者中，大多数人没有得到正式的诊断，因此无法获得有益的治疗。目前国民保健服务的方法是缓慢的（通常超过12个月），而且往往是低质量的。该项目将开发一种新型的数字医疗保健系统，使痴呆症的诊断能够快速、经济有效地在疾病过程的早期进行。它将基于计算机的记忆和思维测试与计算机化的核磁共振脑部扫描分析结合起来，这种方法已经在研究中使用了好几年。它将在诊断方面提供支持，向治疗所有患者的医生提供目前仅在高度专业化的中心提供的高质量信息，目的是将诊断时间缩短至3个月。我们将建立和测试原型并展示其价值，然后开发出可以在全国推广的精致原型。